1. Home
  2. AGNT vs CADL Comparison

AGNT vs CADL Comparison

Compare AGNT & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AGNT Inc. Common Stock

AGNT

AGNT Inc. Common Stock

SELL

Current Price

$2.67

Market Cap

468.6M

Sector

Finance

ML Signal

SELL

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$5.40

Market Cap

455.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGNT
CADL
Founded
2008
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
468.6M
455.8M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
AGNT
CADL
Price
$2.67
$5.40
Analyst Decision
Buy
Strong Buy
Analyst Count
3
10
Target Price
$5.75
★ $17.67
AVG Volume (30 Days)
★ 1.6M
1.4M
Earning Date
11-05-2026
11-12-2026
Dividend Yield
★ 7.07%
N/A
EPS Growth
N/A
★ 58.62
EPS
★ N/A
N/A
Revenue
★ $500,147,681.00
$125,000.00
Revenue This Year
$3.76
N/A
Revenue Next Year
$7.08
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 220.39
N/A
52 Week Low
$2.67
$4.35
52 Week High
$5.79
$14.00

Technical Indicators

Market Signals
Indicator
AGNT
CADL
Relative Strength Index (RSI) 33.49 27.40
Support Level N/A $4.62
Resistance Level $4.20 $5.51
Average True Range (ATR) 0.29 0.72
MACD -0.11 -0.26
Stochastic Oscillator 0.59 4.41

Price Performance

Historical Comparison
AGNT
CADL

About AGNT AGNT Inc. Common Stock

AGNT Inc is a multi-model real estate platform, with brands including eXp Realty, eXp Commercial, NextHome, FrameVR.io, and SUCCESS Enterprises. The group prioritizes transparency, innovation, and long-term value for agents, franchise owners, staff, and shareholders.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: